Physician profile
Peter Morrison
NPI 1689785073
$2,205.30
in general payments reported to CMS, 2019-2025
28 companies · $406 in 2025
The $406 reported for 2025 was more than what 75% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $314 · 2021: $418 · 2022: $367 · 2023: $201 · 2024: $229 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $836.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $306.72 | 2019-2025 | Relistor |
| Forte Bio-Pharma LLC | $299.75 | 2021-2025 | Prolate, Nalocet, Tanlor |
| Supernus Pharmaceuticals, INC. | $168.66 | 2020-2022 | |
| Abbvie INC. | $147.01 | 2022-2025 | |
| Collegium Pharmaceutical, INC. | $143.39 | 2019-2023 | Xtampza |
| Allergan, INC. | $118.21 | 2020 | |
| Medtronic, INC. | $93.93 | 2025 | Intellis Adaptivestim |
| Spr Therapeutics, INC | $93.93 | 2025 | Sprint Pns System |
| Lilly USA, LLC | $93.10 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $83.17 | 2022-2024 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $79.99 | 2021 | |
| Almatica Pharma LLC | $66.03 | 2021-2023 | Gralise |
| Eisai INC. | $55.23 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $53.31 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.22 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $52.15 | 2022 | |
| Pfizer INC. | $50.81 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $43.22 | 2022 | |
| Scilex Pharmaceuticals INC. | $35.81 | 2021-2024 | |
| Redhill Biopharma INC. | $28.30 | 2021-2022 | |
| Daiichi Sankyo INC. | $23.45 | 2019 | |
| Amgen INC. | $21.77 | 2022 | |
| Valinor Pharma, LLC | $17.65 | 2025 | Movantik |
| Grt US Holding, INC. | $17.19 | 2020 | |
| Virtus Pharmaceuticals LLC | $17.14 | 2023 | Levorphanol Tartrate |
| Zyla Life Sciences, INC. | $15.83 | 2019 | |
| Assertio Therapeutics, INC. | $14.51 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Morrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.